Vol 17 - Numéro 2 Supplément 1 - octobre 2025
P. 2S1-2S358© SPLF
Cours du Groupe d'Oncologie thoracique de Langue Française - GOLF 2025
Rev. Mal. Respir. actual October 2025; 17(2S1): i. Publication en ligne : 8 October 2025
PDF HTML
Rev. Mal. Respir. actual October 2025; 17(2S1): ii. Publication en ligne : 8 October 2025
PDF HTML accès libre
Rev. Mal. Respir. actual October 2025; 17(2S1): iii. Publication en ligne : 8 October 2025
PDF HTML
Editorial: The 2025 GOLF Conference
M. Duruisseaux, S. Couraud, A.-C. Toffart, A. Swalduz
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S1. Publication en ligne : 8 October 2025
Smoking cessation in daily practice
A.-M. Ruppert, D. Glesener
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S3. Publication en ligne : 8 October 2025
Epidemiology and environmental and occupational risk factors of lung cancer
J.-C. Pairon, L. Boudet, F. Delva, P. Andujar
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S8. Publication en ligne : 8 October 2025
Pulmonary oncogenesis: molecular foundations and therapeutic implications
C. Ricordel, C. Pierre, Y. Le Guen, H. Lena
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S15. Publication en ligne : 8 October 2025
Genetic predisposition to lung cancer
P. Benusiglio
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S25. Publication en ligne : 8 October 2025
Tissue biomarkers in NSCLC
A. Mansuet-Lupo, K. Leroy, M. Wislez
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S30. Publication en ligne : 8 October 2025
Lung cancer: which molecular biology work up?
C. Leonce, F. Escande, K. Leroy, C. Mascaux, C. Descarpentries, O. Farchi, H. Blons, M. Beau-Faller
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S38. Publication en ligne : 8 October 2025
The 9th TNM classification of thoracic oncology
A. Agrafiotis, B. Grigoriu, P. Van Schil
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S46. Publication en ligne : 8 October 2025
Assessment of lung cancer: which radiological evaluation?
G. Ferretti, L. Ruez-Lantuejoul, E. Reymond, A.-C. Toffart, A. Khalil, V. Gounant, S. Boussouar
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S60. Publication en ligne : 8 October 2025
Lung cancer screening
S. Couraud, E. Grolleau, B. Milleron, V. Gounant, O. Leleu
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S68. Publication en ligne : 8 October 2025
When and how to perform lymph node staging?
D. Basille
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S75. Publication en ligne : 8 October 2025
Surgery in early-stage lung cancer in 2024
G. Drevet, E. Gagnepain, J.-M. Maury
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S84. Publication en ligne : 8 October 2025
Focus on stereotactic radiotherapy for the management of localized non-small cell lung cancer
E. Martin, F. Bonnet, M. Rakotosamimanana, C. Chevalier, J. Baude
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S92. Publication en ligne : 8 October 2025
Perioperative treatments for non-small cell lung cancer (NSCLC): current standards and perspectives
J. Slomka, G. Eberst, V. Westeel, M. Wislez
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S98. Publication en ligne : 8 October 2025
Radiotherapy for locally advanced non-small cell lung cancers
I. Martel-Lafay
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S106. Publication en ligne : 8 October 2025
Role of immunotherapy in unresectable stage III NSCLC
E. Giroux Leprieur, M. Pérol, J. Khalifa
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S113. Publication en ligne : 8 October 2025
Place of surgery in the treatment of locally advanced NSCLC
G. Galvaing
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S121. Publication en ligne : 8 October 2025
Non-small-cell oligo-metastatic bronchial cancers, oligo-persistence, oligo-progression, residual disease: what are we talking about? What management?
L. Bigay-Game, L. Alvarez, A. Rabeau, V. Gounant, C. Daigmorte, C. Mehlman, C. Joseph, Y.M. Xu, J.E. Simon, G. Zalcman
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S127. Publication en ligne : 8 October 2025
How to irradiate a patient under systemic treatment (targeted therapy, immunotherapy, ADC)?
C. Le Péchoux, A. Mavrikios, A. Botticella, D. Lavigne, A. Camps-Malea, P. Abdayem, P. Lavaud, M. Frelaut, C. Parisi, J. Remon-Masip, A. Levy
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S143. Publication en ligne : 8 October 2025
Therapeutic algorithm for NSCLC without molecular anomaly actuatable in first-line treatment
A.-C. Toffart, J. Mazières, M. Pérol, E. Berton, A. Cortot, D. Moro-Sibilot
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S151. Publication en ligne : 8 October 2025
Treatment algorithm after frontline treatment in NSCLC without oncogenic addiction
M. Pérol, D. Moro-Sibilot
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S160. Publication en ligne : 8 October 2025
Antibody drug conjugates in non-small cell lung cancer: where do we stand?
D. Bruyat, P. Tomasini
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S171. Publication en ligne : 8 October 2025
Innovative therapeutic antibodies in non-small cell lung cancer: beyond conventional targets
E. Pons-Tostivint, J. Bennouna
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S180. Publication en ligne : 8 October 2025
Therapeutic algorithm of EGFR mutation driven non-small cell carcinoma
M. Ferreira, V. Fallet, S. Baldacci, A.B. Cortot, J. Cadranel
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S192. Publication en ligne : 8 October 2025
Therapeutic algorithm for non-small cell lung cancers with ALK, ROS1 and RET fusions
A. Swalduz, A. Cortot, M. Duruisseaux
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S213. Publication en ligne : 8 October 2025
Non-Small Cell Lung Cancers with KRAS mutations
A. Chour, C. Lafitte, M. Boussageon, T. Pierret, M. Duruisseaux
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S221. Publication en ligne : 8 October 2025
Non-small cell lung cancer with other targetable mutations ( BRAF, MET, HER2 )
A. Mogenet, A. Cortot, P. Abdayem, D. Planchard, L. Greillier
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S230. Publication en ligne : 8 October 2025
Classification of pulmonary neuroendocrine neoplasms and impacts on clinical practice
S. Lantuejoul, F. Forest, F. Damiola, D. Moro-Sibilot, L. Falchero
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S237. Publication en ligne : 8 October 2025
Management of limited-stage small cell lung cancer: an update
S. Thureau, E. Nicolas, C. Faivre-Finn, E. Giroux Leprieur, S. Ocak, P. Fournel, E. Negre, B. Roch, C. Le Péchoux
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S245. Publication en ligne : 8 October 2025
Exensive-stage small cell lung cancer: what’s new?
D. Moro-Sibilot, S. Ocak, C. Ardin, E. Berton, P. Fournel, A.-C. Toffart
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S253. Publication en ligne : 8 October 2025
Pulmonary neuroendocrine neoplasias excluding small cell lung cancers: carcinoid tumors and large-cell neuroendocrine carcinomas
L. Odier, M. Darrason, M. Duruisseaux, T. Walter, L. Gérinière, A. Durand, D. Arpin
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S261. Publication en ligne : 8 October 2025
Pleural mesothelioma: therapeutic algorithm
M. Locatelli-Sanchez, A. Scherpereel, N. Venissac, S. Humez, L. Ulmer, S. Brosseau, X. Dhalluin, D. Nunes, V. Gounant, S. Lantuejoul, G. Zalcman
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S270. Publication en ligne : 8 October 2025
Thymic tumors: surgical management
G. Drevet, E. Gagnepain, L. Chalabreyse, C. Lafite, T. Pierret, J.-M. Maury
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S279. Publication en ligne : 8 October 2025
Thymic tumors: systemic treatments and role of radiotherapy
T. Pierret, M. Duruisseaux, C. Lafitte, M. Boussageon, L. Chalabreysse, J.-M. Maury, M. Le Bon, B. Besse, N. Girard
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S286. Publication en ligne : 8 October 2025
Brain metastases and carcinomatous meningitis of bronchial cancers
C. Decroisette, E. Perrot, P. Tomasini
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S294. Publication en ligne : 8 October 2025
Admission to critical care units and level of life-sustaining therapies: application to lung cancer?
G. Dumas, C. Ardin, G. Berardi, F. Gonzalez, A.-C. Toffart
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S305. Publication en ligne : 8 October 2025
Interventional bronchoscopy (debulking and prothesis)
C. Lorut, A. Lefebvre, H. Joumaa, J. Marey, F. Giraud, L. Regard
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S311. Publication en ligne : 8 October 2025
Systemic management of lung cancer in elderly
L. Pabst, R. Corre, E. Quoix, C. Mascaux
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S318. Publication en ligne : 8 October 2025
Special Populations: Patients with Performance Status 2 or higher
V. Gounant, L. Alvarez, Y.M. Xu, C. Mehlman, L. Nicolas, S. Guillerm, P. Mordant, G. Zalcman
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S329. Publication en ligne : 8 October 2025
Thromboembolic diseases and lung cancer
G. Poenou, C. Marie-Sainte, A.-L. Desage, C. Gravelier, S. Accassat, L. Bertoletti
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S341. Publication en ligne : 8 October 2025
Lung cancers associated with fibrosing interstitial lung disease
B. Duchemann, J. Cadranel, A. Paix, L. Matton, M. Didier, D. Radu, M. Kambouchner, K. Chouahnia, J. Behr, P.-Y. Brillet, H. Nunes
Rev. Mal. Respir. actual October 2025; 17(2S1): 2S350. Publication en ligne : 8 October 2025